EA
ECYT

Emerald Acquisition’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Emerald Acquisition’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20,100
Closed -$64K – 3106
2016
Q2 		$64K Buy
+20,100
New +$73.7K ﹤0.01% 2893

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Emerald Acquisition's ECYT Position: Q3 2016 in Review

Emerald Acquisition sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2016, closing a stake of 20,100 shares — an estimated $64K sold.

Emerald Acquisition first reported a position in ECYT in Q2 2016 and held it in 1 quarter. The position peaked at $64K in Q2 2016. 90 funds tracked by Wall St. Rank hold ECYT as of Q3 2016.

  • Emerald Acquisition reported no remaining Endocyte, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 20,100 Endocyte, Inc. Common Stock shares in Q3 2016, an estimated $64K.
  • Emerald Acquisition first reported a position in Endocyte, Inc. Common Stock in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Endocyte, Inc. Common Stock position peaked at $64K in Q2 2016.
  • 90 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.